The research of Mohsen Khosravi Maharlooei focuses on immunoengineering. Dr. Khosravi develops and applies novel ways of inducing immune tolerance. He uses integrated approaches that combine laboratory, clinical and computational methods. Engineering of immune cells such as regulatory T cells called Tregs and hematopoietic stem cells called HSCs are an integral part of these novel methods. Engineering approaches such as CRISPR and viral transduction are implemented to engineer the immune cells. Novel discovery methods such as CRISPR screening are employed to identify new target genes. Transcriptomics, epigenomics and proteomics data analysis are implemented to evaluate immune cells from clinical samples, humanized mice and in vitro assays.